EGFR and non-small cell lung carcinoma: A total of 52 patients diagnosed with EGFR-mutated (Exon 19 deletion or Exon 21 L858R) locally advanced or metastatic NSCLC and receiving aumolertinib treatment were successively screened from September 2022 (Figure 1).